Article Text

other Versions

PDF
Molecular targets of current and prospective heart failure therapies
  1. Elie R Chemaly,
  2. Roger J Hajjar,
  3. Larissa Lipskaia
  1. Cardiovascular Research Center, Mount Sinai School of Medicine, New York, New York, USA
  1. Correspondence to Dr Larissa Lipskaia, Cardiovascular Research Center, Mount Sinai School of Medicine, New York, NY 10029, USA; larissa.lipskaia{at}mssm.edu

Abstract

Heart failure (HF) is a vicious circle in which an original insult leading to mechanical cardiac dysfunction initiates multiple morphological, biochemical and molecular pathological alterations referred to as cardiac remodelling. Remodelling leads to further deterioration of cardiac function and functional reserve. Interrupting or reversing cardiac remodelling is a major therapeutic goal of HF therapies. The role of molecules and molecular pathways in cardiac remodelling and HF has been extensively studied. Multiple approaches are now used or investigated in HF therapy, including pharmacological therapy, device therapy, gene therapy, cell therapy and biological therapy targeting cytokines and growth factors. This review explores the molecular targets and molecular bases of current and prospective therapies in HF.

  • Pharmacology

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.